NRXS
NeurAxis, Inc.NASDAQHealthcareAs of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
19.80
P/S
23.23
EV/EBITDA
-10.22
DCF Value
$-3.98
FCF Yield
-7.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
84.2%
Operating Margin
-219.4%
Net Margin
-218.5%
ROE
-306.0%
ROA
-121.8%
ROIC
-204.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $968.1K | $-1.7M | $-0.16 |
| FY 2025 | $3.6M | $-7.8M | $-0.95 |
| Q3 2025 | $811.4K | $-2.1M | $-0.24 |
| Q2 2025 | $894.1K | $-1.7M | $-0.22 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.49
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.